Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. reports developments tied to FB102, its proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Recurring updates cover clinical development in celiac disease, non-segmental vitiligo and alopecia areata, including regulatory designations such as Fast Track status in celiac disease.
Company news also includes quarterly and annual financial results, research and development spending tied to FB102, public financing activity, investor meeting participation and Nasdaq-required disclosures for equity inducement awards under its 2020 Inducement Equity Incentive Plan.
Forte Biosciences (NASDAQ: FBRX) reported Q3 2025 results and a clinical update on FB102 on November 14, 2025. The company said the U.S. IND is open and enrollment for the FB102 Phase 2 celiac disease trial has expanded to U.S. sites, with topline results expected in 2026. Two Phase 1b studies (vitiligo, alopecia areata) are ongoing with topline data expected in 1H26 and 2026, respectively. Q3 R&D expense was $15.2M and cash and equivalents were $93.4M as of September 30, 2025.
Forte Biosciences (NASDAQ: FBRX) will present at three upcoming healthcare conferences in November–December 2025. Presentations:
- Guggenheim 2nd Annual Healthcare Innovation Conference — InterContinental Boston, Boston, MA — Mon, Nov 10, 3:30–3:55 PM ET
- TD Cowen Immunology and Inflammation Summit — virtual — Wed, Nov 12, 2:00–2:20 PM ET
- 8th Annual Evercore Healthcare Conference — Loews Hotel, Coral Gables, FL — Thu, Dec 4, 11:15–11:35 AM ET
Forte is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. Investor contacts are provided for media and investor inquiries.
Forte Biosciences (NASDAQ: FBRX) on October 3, 2025 announced equity inducement awards under NASDAQ Listing Rule 5635(c)(4).
The Compensation Committee granted options to purchase a total of 125,000 shares of common stock to new non‑executive employees as material inducements to join the company. Awards were made under the 2020 Inducement Equity Incentive Plan and related agreements.
Vesting is over four years: 25% vests on the one‑year anniversary of each optionee’s start date, with the remaining 75% vesting in approximately equal monthly increments over the following 36 months, subject to continuous employment.
Forte Biosciences (NASDAQ: FBRX) presented additional data from their FB102 Phase 1b celiac disease trial at the Tampere Celiac Disease Symposium 2025. The presentation highlighted significant positive results for FB102, including a decline in TCR γδ density of 1.5 compared to a 3.9 increase in placebo (p=0.0007), and reduced Ki67-positive intraepithelial cell density compared to placebo (p=0.0006).
The study demonstrated a 95% reduction in NK cells following FB102 treatment, indicating successful IL-15 pathway inhibition. The company is currently conducting a Phase 2 trial for celiac disease with topline data expected in 2026, alongside trials for vitiligo and alopecia areata with data expected in 2026.
[ "Statistically significant reduction in TCR γδ density (p=0.0007) compared to placebo", "Significant decrease in Ki67-positive intraepithelial cell density (p=0.0006) versus placebo", "95% reduction in NK cells following FB102 treatment", "Pipeline expansion into additional indications (vitiligo and alopecia areata)" ]Forte Biosciences (NASDAQ: FBRX) announced significant progress in its clinical development program for FB102, with three major trial readouts expected in 2026. The company has initiated a phase 2 trial in celiac disease following positive phase 1b results, continues enrollment in a phase 1b vitiligo study with data expected in 1H26, and is launching a phase 1b trial in alopecia areata.
On the financial front, Forte completed a successful public offering in June 2025, raising $69.9 million through the sale of 5.63M shares at $12.00 per share and pre-funded warrants, with an additional $1.7 million from the over-allotment exercise. The company ended Q2 2025 with $106.1 million in cash, reporting a net loss of $(0.96) per share compared to $(6.78) in Q2 2024.
Forte Biosciences (Nasdaq: FBRX), a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering. The offering consists of 5,630,450 shares of common stock priced at $12.00 per share, along with pre-funded warrants for up to 619,606 shares at $11.999 per warrant.
The company has granted underwriters a 30-day option to purchase up to an additional 937,508 shares. The offering is expected to close around June 26, 2025. Forte plans to use the proceeds for working capital, clinical and preclinical development of its product candidate, and other research activities.
Forte Biosciences (Nasdaq: FBRX), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares.
The offering will be managed by TD Cowen, Evercore ISI, Guggenheim Securities, and Chardan as joint book-running managers, with Lucid Capital Markets as co-manager. Proceeds will be used for working capital, clinical and preclinical development of product candidates, and other research activities.
Forte Biosciences (NASDAQ: FBRX) reported its full year 2024 results and provided a clinical update. The company highlighted significant progress in developing FB102, with the completion of a healthy volunteer study and ongoing celiac patient trial, which is progressing well with no dropouts. Topline results are expected in Q2 2025.
Financial highlights include:
- R&D expenses decreased to $21.2M from $21.9M in 2023
- G&A expenses increased to $15.4M from $10.6M in 2023
- Net loss per share improved to $(12.17) from $(24.92)
- Year-end cash position of $58.4M
The company completed a 1:25 reverse stock split in August 2024 and raised $53.0M through an over-subscribed private placement in November 2024. As of December 31, 2024, there were 6.4M shares of common stock and 5.0M prefunded warrants outstanding.